Compare CPRX & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRX | NVTS |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2006 | 2020 |
| Metric | CPRX | NVTS |
|---|---|---|
| Price | $24.79 | $8.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $35.00 | $6.68 |
| AVG Volume (30 Days) | 897.2K | ★ 18.7M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $119,072,803.00 | $45,916,000.00 |
| Revenue This Year | $9.20 | N/A |
| Revenue Next Year | $10.51 | $71.28 |
| P/E Ratio | $14.75 | ★ N/A |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $1.52 |
| 52 Week High | $26.56 | $17.79 |
| Indicator | CPRX | NVTS |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 46.54 |
| Support Level | $22.24 | $7.34 |
| Resistance Level | $24.94 | $9.84 |
| Average True Range (ATR) | 0.66 | 0.77 |
| MACD | 0.18 | -0.13 |
| Stochastic Oscillator | 89.26 | 21.91 |
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.